OncoMatch/Clinical Trials/NCT06414434
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
Is NCT06414434 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BTX-A51 for liposarcoma.
Treatment: BTX-A51 — This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma. The name of the study drug used in this research study is: -BTX-A51 (a type of kinase inhibitor)
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Biomarker criteria
Required: CIC rearrangement
Required: MDM2 amplification
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
wbc >3000/mm3; platelets >75,000μl; anc >1500μl; hgb >9g/dl
Kidney function
creatinine <1.5 x uln or measured crcl of >60ml/m2/1.73 m2
Liver function
total bilirubin <2 x uln; ast/alt <3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify